Product NDC: | 0008-1218 |
Proprietary Name: | Relistor |
Non Proprietary Name: | Methylnaltrexone bromide |
Active Ingredient(s): | 12 mg/.6mL & nbsp; Methylnaltrexone bromide |
Administration Route(s): | SUBCUTANEOUS |
Dosage Form(s): | INJECTION, SOLUTION |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 0008-1218 |
Labeler Name: | Wyeth Pharmaceuticals Company, a subsidiary of Pfizer Inc. |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | NDA021964 |
Marketing Category: | NDA |
Start Marketing Date: | 20080801 |
Package NDC: | 0008-1218-01 |
Package Description: | 1 VIAL in 1 CARTON (0008-1218-01) > .6 mL in 1 VIAL |
NDC Code | 0008-1218-01 |
Proprietary Name | Relistor |
Package Description | 1 VIAL in 1 CARTON (0008-1218-01) > .6 mL in 1 VIAL |
Product NDC | 0008-1218 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | Methylnaltrexone bromide |
Dosage Form Name | INJECTION, SOLUTION |
Route Name | SUBCUTANEOUS |
Start Marketing Date | 20080801 |
Marketing Category Name | NDA |
Labeler Name | Wyeth Pharmaceuticals Company, a subsidiary of Pfizer Inc. |
Substance Name | METHYLNALTREXONE BROMIDE |
Strength Number | 12 |
Strength Unit | mg/.6mL |
Pharmaceutical Classes | Opioid Antagonist [EPC],Opioid Antagonists [MoA],Quaternary Ammonium Compounds [Chemical/Ingredient] |